Cetuximab promotes anticancer drug toxicity in rhabdomyosarcomas with EGFR amplification in vitro

Yuki Yamamoto, Kazumasa Fukuda, Yasushi Fuchimoto, Yumi Matsuzaki, Yoshirou Saikawa, Yuko Kitagawa, Yasuhide Morikawa, Tatsuo Kuroda

研究成果: Article査読

13 被引用数 (Scopus)

抄録

Overexpression of human epidermal growth factor receptor (EGFR) has been detected in various tumors and is associated with poor outcomes. Combination treatment regimens with EGFR-targeting and cytotoxic agents are a potential therapeutic option for rhabdomyosarcoma (RMS) with EGFR amplification. We investigated the effects of combination treatment with actinomycin D and the EGFR-targeting agent cetuximab in 4 RMS cell lines. All 4 RMS cell lines expressed wild-type K-ras, and 2 of the 4 overexpressed EGFR, as determined by flow cytometry, real-time PCR and direct sequencing. Combination of cetuximab and actinomycin D was highly effective, synergistically inhibiting cell growth with a combination index of less than 1. Moreover, combination treatment with these two reagents increased the rate of apoptosis in EGFR-positive cells. Cetuximab has antitumor activity in EGFR-amplified RMS cells when combined with antitumor reagents, indicating that cetuximab is a potential therapeutic reagent for RMS with EGFR amplification.

本文言語English
ページ(範囲)1081-1086
ページ数6
ジャーナルOncology reports
30
3
DOI
出版ステータスPublished - 2013 9月

ASJC Scopus subject areas

  • 腫瘍学
  • 癌研究

フィンガープリント

「Cetuximab promotes anticancer drug toxicity in rhabdomyosarcomas with EGFR amplification in vitro」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル